Pharmaceutical Deal Landscape Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com04 Dec 2015 • by Natalie Aster
LONDON – Pharmacos use deal activity to increase their R&D activities, enhance commercialisation, improve regulatory approach, expand their geographic presence, and boost sales. The rapid development of biologics, particularly in oncology, has given an enormous boost to activity in the recent past. Whilst the deals number as of 2015 (till July) was lower compared to the volume of deals as of 2014, deal value in 2015 has already surpassed that of 2014. Over the analysis period, though strategic deals were more widespread, M&A deals had the highest deal value. Partnerships were the most common type of deal activity, but their deal value stood at the lowest level. Region-wise, North America took the lead, followed by Europe and APAC. Amid the key deals taking place in the pharmaceutical world one can name the acquisition of Allergen Inc by Actavis plc, asset swaps between Novartis AG and GlaxoSmithKline plc, and the partnership between Merck and Pfizer.
In-demand study “Pharmaceutical Deal Trends (2010–2015) and In-Depth Analysis of Recent Deal Activity” developed by CBR Pharma Insights discusses deal-making trends for a set of deal types, like M&As and strategic alliances. It also discusses the preference by deal type, alongside disclosed deal values from 2010 to July 2015, covering start-up firms, mid-level players, and major players.
The report provides true insights into pharma deals activity through a comprehensive assessment of today’s pharmaceutical industry, besides focusing on the most lucrative regions and therapy fields for both strategic and M&A deals. It includes a scrupulous analysis of top players, limelighting companies engaged in strategic alliance and M&A deals, essential deal activity for all types of deals, and also the most numerous and highest-value deals entered into by the globe’s leading pharmacos. The study provides a refined understanding of how the present-day deals market is evolving, examining deals based on molecule type, route of administration, and development stage. It further identifies the most appropriate deal activity for dealing with challenges and improving performance, comprising a detailed analysis of the rationale behind major recent deals.
Pharmaceutical Deal Trends (2010–2015) and In-Depth Analysis of Recent Deal Activity
Published: October, 2015
Price: US$ 2,995.00
More topical studies by the publisher can be found at CBR Pharma Insights page.